3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Labetalol.
Abiraterone
The serum concentration of Labetalol can be increased when it is combined with Abiraterone.
Acebutolol
Acebutolol may increase the orthostatic hypotensive activities of Labetalol.
Advertisement
Aceclofenac
Aceclofenac may decrease the antihypertensive activities of Labetalol.
Acemetacin
The therapeutic efficacy of Labetalol can be decreased when used in combination with Acemetacin.
Acepromazine
Acepromazine may increase the hypotensive activities of Labetalol.
Advertisement
Aceprometazine
Aceprometazine may increase the hypotensive activities of Labetalol.
Acetohexamide
Labetalol may increase the hypoglycemic activities of Acetohexamide.
Acetyl salicylate
Acetylsalicylic acid may decrease the antihypertensive activities of Labetalol.
Advertisement
Acetylcholine
The risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.
Acetylcholine Chloride
The risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.
Acetyldigitoxin
Labetalol may increase the bradycardic activities of Acetyldigitoxin.
Adapalene
Adapalene may decrease the antihypertensive activities of Labetalol.
Adrafinil
Labetalol may decrease the vasoconstricting activities of Adrafinil.
Albuterol
Labetalol may decrease the vasoconstricting activities of Salbutamol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.
Alfentanil
Alfentanil may increase the bradycardic activities of Labetalol.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Labetalol.
Aliskiren
Labetalol may increase the hypotensive activities of Aliskiren.
Alminoprofen
Alminoprofen may decrease the antihypertensive activities of Labetalol.
Alprenolol
Alprenolol may increase the orthostatic hypotensive activities of Labetalol.
Ambenonium
Ambenonium may increase the bradycardic activities of Labetalol.
Ambrisentan
Labetalol may increase the hypotensive activities of Ambrisentan.
Amifostine
Labetalol may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Labetalol may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Labetalol.
Amiodarone
The therapeutic efficacy of Labetalol can be increased when used in combination with Amiodarone.
Amlodipine
Amlodipine may increase the hypotensive activities of Labetalol.
Amobarbital
The serum concentration of Labetalol can be decreased when it is combined with Amobarbital.
Amodiaquine
The metabolism of Labetalol can be decreased when combined with Amodiaquine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Labetalol.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Labetalol.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Labetalol.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Labetalol is combined with Amyl Nitrite.
Antipyrine
Antipyrine may decrease the antihypertensive activities of Labetalol.
Apazone
Azapropazone may decrease the antihypertensive activities of Labetalol.
Apomorphine
Apomorphine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Apraclonidine
Labetalol may decrease the vasoconstricting activities of Apraclonidine.
Apremilast
Apremilast may decrease the antihypertensive activities of Labetalol.
Arbutamine
Labetalol may decrease the vasoconstricting activities of Arbutamine.
Arformoterol
Labetalol may decrease the vasoconstricting activities of Arformoterol.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Labetalol.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Labetalol.
Artemether
The metabolism of Labetalol can be decreased when combined with Artemether.
Aspirin
Acetylsalicylic acid may decrease the antihypertensive activities of Labetalol.
Atenolol
Atenolol may increase the orthostatic hypotensive activities of Labetalol.
Atomoxetine
Atomoxetine may increase the hypertensive activities of Labetalol.
Avanafil
Avanafil may increase the hypotensive activities of Labetalol.
Azelastine
Azelastine may decrease the antihypertensive activities of Labetalol.
Azilsartan
The risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.
Balsalazide
Balsalazide may decrease the antihypertensive activities of Labetalol.
Barbexaclone
The serum concentration of Labetalol can be decreased when it is combined with Barbexaclone.
Barbital
The serum concentration of Labetalol can be decreased when it is combined with Barbital.
Benazepril
Benazepril may increase the hypotensive activities of Labetalol.
Bencyclane
The risk or severity of hypotension can be increased when Labetalol is combined with Bencyclane.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Labetalol.
Benzphetamine
Benzphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Benzydamine
Benzydamine may decrease the antihypertensive activities of Labetalol.
Bepridil
Labetalol may increase the hypotensive activities of Bepridil.
Beractant
Labetalol may increase the bradycardic activities of Beractant.
Betaxolol
Betaxolol may increase the orthostatic hypotensive activities of Labetalol.
Bethanechol
The risk or severity of adverse effects can be increased when Labetalol is combined with Bethanechol.
Bethanidine
Bethanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Bimatoprost
Labetalol may increase the hypotensive activities of Bimatoprost.
Bisoprolol
Bisoprolol may increase the orthostatic hypotensive activities of Labetalol.
Bitolterol
Labetalol may decrease the vasoconstricting activities of Bitolterol.
Bitolterol Mesylate
Labetalol may decrease the vasoconstricting activities of Bitolterol.
Bopindolol
Bopindolol may increase the orthostatic hypotensive activities of Labetalol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Labetalol.
Bosentan
Bosentan may increase the hypotensive activities of Labetalol.
Bretylium
Bretylium may increase the bradycardic activities of Labetalol.
Brimonidine
Brimonidine may increase the antihypertensive activities of Labetalol.
Bromfenac
Bromfenac may decrease the antihypertensive activities of Labetalol.
Bromocriptine
Bromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Bufexamac
Bufexamac may decrease the antihypertensive activities of Labetalol.
Bumetanide
The risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.
Bunazosin
Labetalol may increase the antihypertensive activities of Bunazosin.
Bupivacaine
The serum concentration of Bupivacaine can be increased when it is combined with Labetalol.
Bupranolol
Bupranolol may increase the orthostatic hypotensive activities of Labetalol.
Bupropion
The metabolism of Labetalol can be decreased when combined with Bupropion.
Cabergoline
Labetalol may increase the vasoconstricting activities of Cabergoline.
Cafedrine
Labetalol may increase the hypotensive activities of Cafedrine.
Calcium Carbimide
The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Labetalol.
Calfactant
Labetalol may increase the bradycardic activities of Calfactant.
Canagliflozin
The risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.
Candesartan
Labetalol may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Labetalol may increase the hypotensive activities of Candesartan cilexetil.
Captopril
Labetalol may increase the hypotensive activities of Captopril.
Carbachol
The risk or severity of adverse effects can be increased when Labetalol is combined with Carbachol.
Carprofen
Carprofen may decrease the antihypertensive activities of Labetalol.
Carteolol
Carteolol may increase the orthostatic hypotensive activities of Labetalol.
Carvedilol
Labetalol may increase the antihypertensive activities of Carvedilol.
Celecoxib
The metabolism of Labetalol can be decreased when combined with Celecoxib.
Celiprolol
Celiprolol may increase the orthostatic hypotensive activities of Labetalol.
Ceritinib
Labetalol may increase the bradycardic activities of Ceritinib.
Cevimeline
The risk or severity of adverse effects can be increased when Labetalol is combined with Cevimeline.
Chloroquine
The metabolism of Labetalol can be decreased when combined with Chloroquine.
Chlorothiazide
Labetalol may increase the hypotensive activities of Chlorothiazide.
Chlorpromazine
The metabolism of Labetalol can be decreased when combined with Chlorpromazine.
Chlorpropamide
Labetalol may increase the hypoglycemic activities of Chlorpropamide.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Labetalol.
Cholecalciferol
The metabolism of Labetalol can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
Choline magnesium trisalicylate may decrease the antihypertensive activities of Labetalol.
Cicletanine
Labetalol may increase the hypotensive activities of Cicletanine.
Cilazapril
Labetalol may increase the hypotensive activities of Cilazapril.
Cimetidine
The metabolism of Labetalol can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Labetalol can be decreased when combined with Cinacalcet.
Cinnarizine
The risk or severity of hypotension can be increased when Labetalol is combined with Cinnarizine.
Citalopram
The metabolism of Labetalol can be decreased when combined with Citalopram.
Clemastine
The metabolism of Labetalol can be decreased when combined with Clemastine.
Clenbuterol
The risk or severity of adverse effects can be increased when Labetalol is combined with Clenbuterol.
Clevidipine
The risk or severity of hypotension can be increased when Labetalol is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of hypotension can be increased when Labetalol is combined with Clevidipine.
Clobazam
The metabolism of Labetalol can be decreased when combined with Clobazam.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Labetalol.
Clomipramine
The metabolism of Labetalol can be decreased when combined with Clomipramine.
Clonidine
Clonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Clonixin
Clonixin may decrease the antihypertensive activities of Labetalol.
Clotrimazole
The metabolism of Labetalol can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Labetalol can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Labetalol can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Labetalol can be decreased when combined with Cocaine.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Labetalol.
Crizotinib
Labetalol may increase the bradycardic activities of Crizotinib.
Cryptenamine
Labetalol may increase the hypotensive activities of Cryptenamine.
Curcumin
Curcumin may decrease the antihypertensive activities of Labetalol.
Cyclandelate
The risk or severity of hypotension can be increased when Labetalol is combined with Cyclandelate.
Cyclopenthiazide
Labetalol may increase the hypotensive activities of Cyclopenthiazide.
Cyclothiazide
Labetalol may increase the hypotensive activities of Cyclothiazide.
Dapagliflozin
The risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.
Darifenacin
The metabolism of Labetalol can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Labetalol can be increased when it is combined with Darunavir.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Labetalol.
Delavirdine
The metabolism of Labetalol can be decreased when combined with Delavirdine.
Demecarium
Demecarium may increase the bradycardic activities of Labetalol.
Deserpidine
Labetalol may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Labetalol.
Desipramine
The metabolism of Labetalol can be decreased when combined with Desipramine.
Deslanoside
Labetalol may increase the bradycardic activities of Deslanoside.
Desvenlafaxine
The serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.
Dexmedetomidine
Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Diazoxide
Diazoxide may increase the hypotensive activities of Labetalol.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Labetalol is combined with Diclofenamide.
Diclofenac
Diclofenac may decrease the antihypertensive activities of Labetalol.
Diflunisal
Diflunisal may decrease the antihypertensive activities of Labetalol.
Digitoxin
Labetalol may increase the bradycardic activities of Digitoxin.
Digoxin
Labetalol may increase the bradycardic activities of Digoxin.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Labetalol.
Dihydroergotamine
Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Diltiazem
Diltiazem may increase the hypotensive activities of Labetalol.
Dinutuximab
The risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.
Diphenhydramine
The metabolism of Labetalol can be decreased when combined with Diphenhydramine.
Dipivefrin
Dipivefrin may increase the atrioventricular blocking (AV block) activities of Labetalol.
Dipyridamole
Dipyridamole may increase the bradycardic activities of Labetalol.
Dipyrone
Metamizole may decrease the antihypertensive activities of Labetalol.
Disopyramide
Disopyramide may increase the bradycardic activities of Labetalol.
Distigmine
Distigmine may increase the bradycardic activities of Labetalol.
Dobutamine
The risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.
Donepezil
Donepezil may increase the bradycardic activities of Labetalol.
Dopamine
The risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.
Dopexamine
Labetalol may decrease the vasoconstricting activities of Dopexamine.
Dorzolamide
Labetalol may increase the hypotensive activities of Dorzolamide.
Dothiepin
The metabolism of Labetalol can be decreased when combined with Dosulepin.
Doxazosin
Doxazosin may increase the antihypertensive activities of Labetalol.
Dronedarone
Dronedarone may increase the bradycardic activities of Labetalol.
Droxicam
Droxicam may decrease the antihypertensive activities of Labetalol.
Droxidopa
Droxidopa may increase the atrioventricular blocking (AV block) activities of Labetalol.
Duloxetine
Labetalol may increase the orthostatic hypotensive activities of Duloxetine.
Echothiophate
Echothiophate may increase the bradycardic activities of Labetalol.
Edrophonium
Edrophonium may increase the bradycardic activities of Labetalol.
Eliglustat
The metabolism of Labetalol can be decreased when combined with Eliglustat.
Empagliflozin
The risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.
Enalapril
Enalapril may increase the hypotensive activities of Labetalol.
Enalaprilat
Labetalol may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Labetalol may increase the hypotensive activities of Enalaprilat.
Ephedrine
The risk or severity of adverse effects can be increased when Labetalol is combined with Ephedrine.
Epinastine
Labetalol may decrease the vasoconstricting activities of Epinastine.
Epinephrine
Epinephrine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Eplerenone
The risk or severity of adverse effects can be increased when Labetalol is combined with Eplerenone.
Epoprostenol
Labetalol may increase the hypotensive activities of Epoprostenol.
Eprosartan
Labetalol may increase the hypotensive activities of Eprosartan.
ergoloid mesylates, USP
Labetalol may increase the vasoconstricting activities of Ergoloid mesylate.
Ergonovine
Labetalol may increase the vasoconstricting activities of Ergonovine.
Ergotamine
Ergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Esmolol
Esmolol may increase the orthostatic hypotensive activities of Labetalol.
Etanercept
Etanercept may decrease the antihypertensive activities of Labetalol.
Ethacrynate
The risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.
Ethosuximide
The risk or severity of hypotension can be increased when Labetalol is combined with Ethosuximide.
Etilefrine
The risk or severity of adverse effects can be increased when Labetalol is combined with Etilefrine.
Etodolac
Etodolac may decrease the antihypertensive activities of Labetalol.
Etofenamate
Etofenamate may decrease the antihypertensive activities of Labetalol.
Etomidate
Etomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.
Etoricoxib
Etoricoxib may decrease the antihypertensive activities of Labetalol.
Evening primrose oil
Evening primrose oil may decrease the antihypertensive activities of Labetalol.
Felbinac
Felbinac may decrease the antihypertensive activities of Labetalol.
Felodipine
Labetalol may increase the hypotensive activities of Felodipine.
Fenbufen
Fenbufen may decrease the antihypertensive activities of Labetalol.
Fendiline
The risk or severity of hypotension can be increased when Labetalol is combined with Fendiline.
Fenoldopam
Labetalol may increase the hypotensive activities of Fenoldopam.
Fenoprofen
Fenoprofen may decrease the antihypertensive activities of Labetalol.
Fenoterol
The risk or severity of adverse effects can be increased when Labetalol is combined with Fenoterol.
Fentanyl
Fentanyl may increase the bradycardic activities of Labetalol.
Ferulic Acid
Labetalol may increase the hypotensive activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.
Fingolimod
Labetalol may increase the bradycardic activities of Fingolimod.
Floctafenine
The risk or severity of adverse effects can be increased when Labetalol is combined with Floctafenine.
Flunarizine
The risk or severity of hypotension can be increased when Labetalol is combined with Flunarizine.
Fluoxetine
The metabolism of Labetalol can be decreased when combined with Fluoxetine.
Fluphenazine
Fluphenazine may increase the hypotensive activities of Labetalol.
Flurbiprofen
Flurbiprofen may decrease the antihypertensive activities of Labetalol.
Fluspirilene
The risk or severity of hypotension can be increased when Labetalol is combined with Fluspirilene.
Fluvoxamine
The metabolism of Labetalol can be decreased when combined with Fluvoxamine.
Formoterol
Labetalol may decrease the vasoconstricting activities of Formoterol.
Fosinopril
Fosinopril may increase the hypotensive activities of Labetalol.
Furazolidone
Furazolidone may increase the hypotensive activities of Labetalol.
Furosemide
The risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.
Gabapentin
The risk or severity of hypotension can be increased when Labetalol is combined with Gabapentin.
Galantamine
Galantamine may increase the bradycardic activities of Labetalol.
Gallamine Triethiodide
Gallamine Triethiodide may increase the bradycardic activities of Labetalol.
Gallopamil
The risk or severity of hypotension can be increased when Labetalol is combined with Gallopamil.
Ginkgo biloba extract
Ginkgo biloba may increase the bradycardic activities of Labetalol.
Glibornuride
Labetalol may increase the hypoglycemic activities of Glibornuride.
Gliclazide
Labetalol may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Labetalol may increase the hypoglycemic activities of Glimepiride.
Glipizide
Labetalol may increase the hypoglycemic activities of Glipizide.
Gliquidone
Labetalol may increase the hypoglycemic activities of Gliquidone.
Glyburide
Labetalol may increase the hypoglycemic activities of Glyburide.
Guanabenz
Guanabenz may increase the atrioventricular blocking (AV block) activities of Labetalol.
Guanadrel
Guanadrel may increase the hypotensive activities of Labetalol.
Guanethidine
Labetalol may increase the hypotensive activities of Guanethidine.
Guanfacine
Guanfacine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Haloperidol
The metabolism of Labetalol can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Labetalol.
Hexobarbital
The serum concentration of Labetalol can be decreased when it is combined with Hexobarbital.
Hexoprenaline
Labetalol may decrease the vasoconstricting activities of Hexoprenaline.
Hydralazine
Hydralazine may increase the hypotensive activities of Labetalol.
Hydrochlorothiazide
Labetalol may increase the hypotensive activities of Hydrochlorothiazide.
Hydroflumethiazide
Labetalol may increase the hypotensive activities of Hydroflumethiazide.
Hydroxychloroquine
The metabolism of Labetalol can be decreased when combined with Hydroxychloroquine.
Ibuprofen
Ibuprofen may decrease the antihypertensive activities of Labetalol.
Icatibant
Icatibant may decrease the antihypertensive activities of Labetalol.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Labetalol.
Imidapril
Labetalol may increase the hypotensive activities of Imidapril.
Imipramine
The metabolism of Labetalol can be decreased when combined with Imipramine.
Inamrinone
The risk or severity of hypotension can be increased when Labetalol is combined with Amrinone.
Indapamide
Labetalol may increase the hypotensive activities of Indapamide.
Indinavir
The metabolism of Labetalol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Labetalol can be decreased when combined with Indinavir.
Indobufen
Indobufen may decrease the antihypertensive activities of Labetalol.
Indomethacin
Indomethacin may decrease the antihypertensive activities of Labetalol.
Indoramin
Labetalol may increase the antihypertensive activities of Indoramin.
insulin human, rDNA origin
Labetalol may increase the hypoglycemic activities of Insulin Human.
Insulin, Pork
Labetalol may increase the hypoglycemic activities of Insulin Pork.
Insulin, Regular, Pork
Labetalol may increase the hypoglycemic activities of Insulin Pork.
Iproniazid
Iproniazid may increase the hypotensive activities of Labetalol.
Irbesartan
Labetalol may increase the hypotensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Labetalol.
Isoetharine
Labetalol may decrease the vasoconstricting activities of Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Labetalol.
Isoflurophate
Isoflurophate may increase the bradycardic activities of Labetalol.
Isoniazid
The metabolism of Labetalol can be decreased when combined with Isoniazid.
Isoproterenol
The risk or severity of adverse effects can be increased when Labetalol is combined with Isoprenaline.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Labetalol is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Labetalol.
Ivabradine
Labetalol may increase the bradycardic activities of Ivabradine.
Kebuzone
Kebuzone may decrease the antihypertensive activities of Labetalol.
Ketanserin
Ketanserin may increase the hypotensive activities of Labetalol.
Ketoconazole
The metabolism of Labetalol can be decreased when combined with Ketoconazole.
Ketoprofen
Ketoprofen may decrease the antihypertensive activities of Labetalol.
Ketorolac
Ketorolac may decrease the antihypertensive activities of Labetalol.
Lacidipine
Labetalol may increase the hypotensive activities of Lacidipine.
Lacosamide
Labetalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
Lamotrigine
The risk or severity of hypotension can be increased when Labetalol is combined with Lamotrigine.
Lanreotide
Labetalol may increase the bradycardic activities of Lanreotide.
Latanoprost
Labetalol may increase the hypotensive activities of Latanoprost.
Leflunomide
Leflunomide may decrease the antihypertensive activities of Labetalol.
Lercanidipine
Lercanidipine may increase the hypotensive activities of Labetalol.
Levetiracetam
The risk or severity of hypotension can be increased when Labetalol is combined with Levetiracetam.
Levobunolol
The risk or severity of adverse effects can be increased when Labetalol is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Labetalol.
Levodopa
Labetalol may increase the orthostatic hypotensive activities of Levodopa.
Levomilnacipran
The serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.
Levonordefrin
Levonordefrin may increase the atrioventricular blocking (AV block) activities of Labetalol.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Labetalol.
Lidocaine
The serum concentration of Lidocaine can be increased when it is combined with Labetalol.
Limonene, (+)-
(4R)-limonene may decrease the antihypertensive activities of Labetalol.
Linezolid
Linezolid may increase the hypertensive activities of Labetalol.
Lisinopril
Labetalol may increase the hypotensive activities of Lisinopril.
Lisinopril Anhydrous
Labetalol may increase the hypotensive activities of Lisinopril.
Lobeline
The risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.
Lofexidine
Lofexidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Loperamide
The risk or severity of hypotension can be increased when Labetalol is combined with Loperamide.
Lopinavir
The metabolism of Labetalol can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Labetalol can be decreased when combined with Lorcaserin.
Lornoxicam
Lornoxicam may decrease the antihypertensive activities of Labetalol.
Losartan
Labetalol may increase the hypotensive activities of Losartan.
Loxoprofen
Loxoprofen may decrease the antihypertensive activities of Labetalol.
Lucinactant
Labetalol may increase the bradycardic activities of Lucinactant.
Lumefantrine
The metabolism of Labetalol can be decreased when combined with Lumefantrine.
Macitentan
Labetalol may increase the hypotensive activities of Macitentan.
Magnesium Salicylate
Magnesium salicylate may decrease the antihypertensive activities of Labetalol.
Magnesium Sulfate
The risk or severity of hypotension can be increased when Labetalol is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The risk or severity of hypotension can be increased when Labetalol is combined with Magnesium sulfate.
Malathion
Malathion may increase the bradycardic activities of Labetalol.
Manidipine
Labetalol may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.
Masoprocol
Masoprocol may decrease the antihypertensive activities of Labetalol.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Labetalol.
Meclofenamate
Meclofenamic acid may decrease the antihypertensive activities of Labetalol.
Meclofenamic Acid
Meclofenamic acid may decrease the antihypertensive activities of Labetalol.
Mefenamic Acid
Mefenamic acid may decrease the antihypertensive activities of Labetalol.
Mefloquine
Mefloquine may increase the bradycardic activities of Labetalol.
Meloxicam
Meloxicam may decrease the antihypertensive activities of Labetalol.
Memantine
Memantine may increase the bradycardic activities of Labetalol.
Mephentermine
Labetalol may decrease the vasoconstricting activities of Mephentermine.
Mephobarbital
The serum concentration of Labetalol can be decreased when it is combined with Methylphenobarbital.
Mepirodipine
Labetalol may increase the antihypertensive activities of Barnidipine.
Mepivacaine
The serum concentration of Mepivacaine can be increased when it is combined with Labetalol.
Mesalamine
Mesalazine may decrease the antihypertensive activities of Labetalol.
Mesoridazine
Mesoridazine may increase the hypotensive activities of Labetalol.
Metaproterenol
The risk or severity of adverse effects can be increased when Labetalol is combined with Orciprenaline.
Metaraminol
Labetalol may decrease the vasoconstricting activities of Metaraminol.
Methacholine
Labetalol may increase the bronchoconstrictory activities of Methacholine.
Methadone
The metabolism of Labetalol can be decreased when combined with Methadone.
Methamphetamine
Methamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Methazolamide
The risk or severity of adverse effects can be increased when Labetalol is combined with Methazolamide.
Methohexital
The serum concentration of Labetalol can be decreased when it is combined with Methohexital.
Methotrimeprazine
The metabolism of Labetalol can be decreased when combined with Methotrimeprazine.
Methoxamine
Labetalol may decrease the vasoconstricting activities of Methoxamine.
Methsuximide
The risk or severity of hypotension can be increased when Labetalol is combined with Methsuximide.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.
Methyldopa
Labetalol may decrease the vasoconstricting activities of Methyldopa.
METHYLDOPA ANHYDROUS
Labetalol may decrease the vasoconstricting activities of Methyldopa.
Methylene blue
Methylene blue may increase the hypotensive activities of Labetalol.
Methylergonovine
Labetalol may increase the vasoconstricting activities of Methylergometrine.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Labetalol.
Metipranolol
Labetalol may increase the hypotensive activities of Metipranolol.
Metoclopramide
Metoclopramide may increase the bradycardic activities of Labetalol.
Metolazone
Metolazone may increase the hypotensive activities of Labetalol.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Labetalol.
Metyrosine
Labetalol may increase the hypotensive activities of Metyrosine.
Mibefradil
Labetalol may increase the hypotensive activities of Mibefradil.
Midodrine
Labetalol may increase the bradycardic activities of Midodrine.
Midostaurin
The metabolism of Labetalol can be decreased when combined with Midostaurin.
Milnacipran
The serum concentration of Labetalol can be increased when it is combined with Milnacipran.
Minaprine
Minaprine may increase the bradycardic activities of Labetalol.
Minoxidil
Minoxidil may increase the hypotensive activities of Labetalol.
Mirabegron
The metabolism of Labetalol can be decreased when combined with Mirabegron.
Moclobemide
Moclobemide may increase the hypotensive activities of Labetalol.
Moexipril
Labetalol may increase the hypotensive activities of Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Labetalol.
Moricizine
Moricizine may increase the hypotensive activities of Labetalol.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.
Moxonidine
Moxonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
MYCOPHENOLATE
Mycophenolic acid may decrease the antihypertensive activities of Labetalol.
Mycophenolate Mofetil
Mycophenolate mofetil may decrease the antihypertensive activities of Labetalol.
Mycophenolic Acid
Mycophenolic acid may decrease the antihypertensive activities of Labetalol.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Labetalol.
Nabumetone
Nabumetone may decrease the antihypertensive activities of Labetalol.
Nadolol
Nadolol may increase the orthostatic hypotensive activities of Labetalol.
Naftifine
Naftifine may decrease the antihypertensive activities of Labetalol.
Naphazoline
Naphazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.
Naproxen
Naproxen may decrease the antihypertensive activities of Labetalol.
Nebivolol
Nebivolol may increase the orthostatic hypotensive activities of Labetalol.
Nefazodone
The serum concentration of Labetalol can be increased when it is combined with Nefazodone.
Neostigmine
Neostigmine may increase the bradycardic activities of Labetalol.
Nepafenac
Nepafenac may decrease the antihypertensive activities of Labetalol.
Nesiritide
The risk or severity of adverse effects can be increased when Labetalol is combined with Nesiritide.
Nevirapine
The metabolism of Labetalol can be decreased when combined with Nevirapine.
Nialamide
Nialamide may increase the hypotensive activities of Labetalol.
Nicardipine
The metabolism of Labetalol can be decreased when combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Labetalol.
Nicotine
The risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine.
Nicotine Polacrilex
The risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine.
Nifedipine
The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Labetalol.
Niflumic Acid
Niflumic Acid may decrease the antihypertensive activities of Labetalol.
Nilotinib
The metabolism of Labetalol can be decreased when combined with Nilotinib.
Nilvadipine
Labetalol may increase the hypotensive activities of Nilvadipine.
Nimesulide
The risk or severity of hypotension can be increased when Labetalol is combined with Nimesulide.
Nimodipine
Nimodipine may increase the hypotensive activities of Labetalol.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Labetalol.
Nitrendipine
Labetalol may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Labetalol.
Nitroglycerin
The risk or severity of adverse effects can be increased when Labetalol is combined with Nitroglycerin.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Labetalol.
Norepinephrine
Norepinephrine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Nylidrin
The risk or severity of adverse effects can be increased when Labetalol is combined with Nylidrin.
O-PHENANTHROLINE
1,10-Phenanthroline may increase the bradycardic activities of Labetalol.
Obinutuzumab
Labetalol may increase the hypotensive activities of Obinutuzumab.
Octreotide
Octreotide may increase the bradycardic activities of Labetalol.
Octylonium
The risk or severity of hypotension can be increased when Labetalol is combined with Otilonium.
Oenothera biennis seed extract
Evening primrose oil may decrease the antihypertensive activities of Labetalol.
Olmesartan
Olmesartan may increase the hypotensive activities of Labetalol.
Olodaterol
Labetalol may decrease the vasoconstricting activities of Olodaterol.
Olopatadine
Olopatadine may decrease the antihypertensive activities of Labetalol.
Olsalazine
Olsalazine may decrease the antihypertensive activities of Labetalol.
Ouabain
Labetalol may increase the bradycardic activities of Ouabain.
Ovine Digoxin Immune Fab
Labetalol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).
Oxaprozin
Oxaprozin may decrease the antihypertensive activities of Labetalol.
Oxprenolol
Oxprenolol may increase the orthostatic hypotensive activities of Labetalol.
Oxymetazoline
Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.
Oxyphenbutazone
Oxyphenbutazone may decrease the antihypertensive activities of Labetalol.
p-Hydroxyamphetamine
The risk or severity of adverse effects can be increased when Labetalol is combined with Hydroxyamphetamine.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Labetalol.
Paliperidone
Paliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.
Panobinostat
The serum concentration of Labetalol can be increased when it is combined with Panobinostat.
Papaverine
The risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.
Parecoxib
Parecoxib may decrease the antihypertensive activities of Labetalol.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.
Pargyline
Pargyline may increase the hypotensive activities of Labetalol.
Paroxetine
The metabolism of Labetalol can be decreased when combined with Paroxetine.
Parthenolide
Parthenolide may decrease the antihypertensive activities of Labetalol.
Pasireotide
Labetalol may increase the bradycardic activities of Pasireotide.
Peginterferon Alfa-2b
The serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Penbutolol may increase the orthostatic hypotensive activities of Labetalol.
Pentobarbital
The serum concentration of Labetalol can be decreased when it is combined with Pentobarbital.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Labetalol.
Perazine
Perazine may increase the hypotensive activities of Labetalol.
Pergolide
Pergolide may increase the atrioventricular blocking (AV block) activities of Labetalol.
Periciazine
Propericiazine may increase the hypotensive activities of Labetalol.
Perindopril
Labetalol may increase the hypotensive activities of Perindopril.
Perphenazine
Perphenazine may increase the hypotensive activities of Labetalol.
Phenelzine
Phenelzine may increase the hypotensive activities of Labetalol.
Phenmetrazine
The risk or severity of adverse effects can be increased when Labetalol is combined with Phenmetrazine.
Phenobarbital
The serum concentration of Labetalol can be decreased when it is combined with Phenobarbital.
Phenoxybenzamine
Labetalol may increase the hypotensive activities of Phenoxybenzamine.
Phentermine
The risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.
PHENTERMINE RESIN
The risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.
Phentolamine
Labetalol may increase the hypotensive activities of Phentolamine.
Phentolamine Mesylate
Labetalol may increase the hypotensive activities of Phentolamine.
Phenylbutazone
Phenylbutazone may decrease the antihypertensive activities of Labetalol.
Phenylephrine
Labetalol may decrease the vasoconstricting activities of Phenylephrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Labetalol.
Physostigmine
Physostigmine may increase the bradycardic activities of Labetalol.
Pilocarpine
The risk or severity of adverse effects can be increased when Labetalol is combined with Pilocarpine.
Pimecrolimus
Pimecrolimus may decrease the antihypertensive activities of Labetalol.
Pinacidil
Pinacidil may increase the hypotensive activities of Labetalol.
Pinaverium
The risk or severity of hypotension can be increased when Labetalol is combined with Pinaverium.
Pindolol
Pindolol may increase the orthostatic hypotensive activities of Labetalol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Labetalol.
Pirbuterol
Labetalol may decrease the vasoconstricting activities of Pirbuterol.
Pirfenidone
Pirfenidone may decrease the antihypertensive activities of Labetalol.
Piroxicam
Piroxicam may decrease the antihypertensive activities of Labetalol.
Piroxicam-Beta-Cyclodextrin
Piroxicam may decrease the antihypertensive activities of Labetalol.
Polythiazide
Labetalol may increase the hypotensive activities of Polythiazide.
Poractant alfa
Labetalol may increase the bradycardic activities of Poractant alfa.
Practolol
Practolol may increase the orthostatic hypotensive activities of Labetalol.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Labetalol.
Prazosin
Prazosin may increase the antihypertensive activities of Labetalol.
Prenylamine
The risk or severity of hypotension can be increased when Labetalol is combined with Prenylamine.
Primaquine
The metabolism of Labetalol can be decreased when combined with Primaquine.
Primidone
The serum concentration of Labetalol can be decreased when it is combined with Primidone.
Procarbazine
Procarbazine may increase the hypotensive activities of Labetalol.
Procaterol
The risk or severity of adverse effects can be increased when Labetalol is combined with Procaterol.
Prochlorperazine
Prochlorperazine may increase the hypotensive activities of Labetalol.
Promazine
The metabolism of Labetalol can be decreased when combined with Promazine.
Promethazine
Promethazine may increase the hypotensive activities of Labetalol.
Propafenone
The serum concentration of Labetalol can be increased when it is combined with Propafenone.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Labetalol.
Propranolol
Propranolol may increase the orthostatic hypotensive activities of Labetalol.
Proscillaridin
Labetalol may increase the bradycardic activities of Proscillaridin.
Pseudoephedrine
Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Pyridostigmine
Pyridostigmine may increase the bradycardic activities of Labetalol.
Pyridostigmine Bromide
Pyridostigmine may increase the bradycardic activities of Labetalol.
Quetiapine
The risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.
Quinapril
Labetalol may increase the hypotensive activities of Quinapril.
Quinidine
The metabolism of Labetalol can be decreased when combined with Quinidine.
Quinine
The metabolism of Labetalol can be decreased when combined with Quinine.
Racepinephrine
The risk or severity of adverse effects can be increased when Labetalol is combined with Racepinephrine.
Ramipril
Ramipril may increase the hypotensive activities of Labetalol.
Ranolazine
The metabolism of Labetalol can be decreased when combined with Ranolazine.
Rasagiline
Rasagiline may increase the hypotensive activities of Labetalol.
Regorafenib
Regorafenib may increase the bradycardic activities of Labetalol.
Regular Insulin, Human
Labetalol may increase the hypoglycemic activities of Insulin Human.
Remifentanil
Remifentanil may increase the bradycardic activities of Labetalol.
Reproterol
Labetalol may decrease the vasoconstricting activities of Reproterol.
Rescinnamine
Labetalol may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Labetalol.
Resveratrol
Resveratrol may decrease the antihypertensive activities of Labetalol.
Rifampin
The serum concentration of Labetalol can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Labetalol can be decreased when it is combined with Rifapentine.
Rifaximin
The serum concentration of Labetalol can be decreased when it is combined with Rifaximin.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Labetalol.
Riociguat
Labetalol may increase the hypotensive activities of Riociguat.
Risperidone
Labetalol may increase the hypotensive activities of Risperidone.
Ritodrine
The risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine.
Ritonavir
The metabolism of Labetalol can be decreased when combined with Ritonavir.
Rituximab
Labetalol may increase the hypotensive activities of Rituximab.
Rivastigmine
Labetalol may increase the bradycardic activities of Rivastigmine.
Rofecoxib
Rofecoxib may decrease the antihypertensive activities of Labetalol.
Rolapitant
The metabolism of Labetalol can be decreased when combined with Rolapitant.
Ropinirole
Ropinirole may increase the atrioventricular blocking (AV block) activities of Labetalol.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Labetalol.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Labetalol.
Rucaparib
The metabolism of Labetalol can be decreased when combined with Rucaparib.
Ruxolitinib
Ruxolitinib may increase the bradycardic activities of Labetalol.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Labetalol.
Salicylamide
Salicylamide may decrease the antihypertensive activities of Labetalol.
Salicylic Acid
Salicylic acid may decrease the antihypertensive activities of Labetalol.
Salmeterol
Labetalol may decrease the vasoconstricting activities of Salmeterol.
Salsalate
Salsalate may decrease the antihypertensive activities of Labetalol.
Secobarbital
The serum concentration of Labetalol can be decreased when it is combined with Secobarbital.
Selegiline
Selegiline may increase the hypotensive activities of Labetalol.
Selexipag
Labetalol may increase the hypotensive activities of Selexipag.
Serratiopeptidase
Serrapeptase may decrease the antihypertensive activities of Labetalol.
Sertraline
The metabolism of Labetalol can be decreased when combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Labetalol.
Sildenafil
Sildenafil may increase the hypotensive activities of Labetalol.
Silodosin
Labetalol may increase the antihypertensive activities of Silodosin.
Sotalol
Sotalol may increase the orthostatic hypotensive activities of Labetalol.
Spirapril
Labetalol may increase the hypotensive activities of Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.
Sufentanil
Sufentanil may increase the bradycardic activities of Labetalol.
Sulfasalazine
Sulfasalazine may decrease the antihypertensive activities of Labetalol.
Sulindac
Sulindac may decrease the antihypertensive activities of Labetalol.
Suprofen
Suprofen may decrease the antihypertensive activities of Labetalol.
Synephrine
The risk or severity of adverse effects can be increased when Labetalol is combined with Synephrine.
Tacrine
Tacrine may increase the bradycardic activities of Labetalol.
Tadalafil
Tadalafil may increase the hypotensive activities of Labetalol.
Talinolol
Talinolol may increase the orthostatic hypotensive activities of Labetalol.
Tamsulosin
Labetalol may increase the antihypertensive activities of Tamsulosin.
Tedizolid
Tedizolid Phosphate may increase the hypertensive activities of Labetalol.
Tedizolid Phosphate
Tedizolid Phosphate may increase the hypertensive activities of Labetalol.
Telmisartan
Labetalol may increase the hypotensive activities of Telmisartan.
Tenoxicam
Tenoxicam may decrease the antihypertensive activities of Labetalol.
Terazosin
Labetalol may increase the antihypertensive activities of Terazosin.
Terbinafine
The metabolism of Labetalol can be decreased when combined with Terbinafine.
Terbutaline
The risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.
Teriflunomide
Teriflunomide may decrease the antihypertensive activities of Labetalol.
Terlipressin
Labetalol may increase the hypotensive activities of Terlipressin.
Tetrahydrocannabinol
Dronabinol may increase the tachycardic activities of Labetalol.
Tetrahydrozoline
The risk or severity of adverse effects can be increased when Labetalol is combined with Tetryzoline.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Labetalol.
Theodrenaline
Labetalol may increase the hypotensive activities of Theodrenaline.
Thiamylal
The serum concentration of Labetalol can be decreased when it is combined with Thiamylal.
Thiethylperazine
Thiethylperazine may increase the hypotensive activities of Labetalol.
Thiopental
The serum concentration of Labetalol can be decreased when it is combined with Thiopental.
Thiopental Sodium
The serum concentration of Labetalol can be decreased when it is combined with Thiopental.
Thioproperazine
Thioproperazine may increase the hypotensive activities of Labetalol.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Labetalol.
Tiaprofenic Acid
Tiaprofenic acid may decrease the antihypertensive activities of Labetalol.
Tibolone
Labetalol may increase the hypotensive activities of Tibolone.
Ticlopidine
The metabolism of Labetalol can be decreased when combined with Ticlopidine.
Timolol
Timolol may increase the orthostatic hypotensive activities of Labetalol.
Timolol Anhydrous
Timolol may increase the orthostatic hypotensive activities of Labetalol.
Tipranavir
The metabolism of Labetalol can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.
Tofacitinib
Tofacitinib may increase the bradycardic activities of Labetalol.
Tolazamide
Labetalol may increase the hypoglycemic activities of Tolazamide.
Tolazoline
Labetalol may increase the hypotensive activities of Tolazoline.
Tolbutamide
Labetalol may increase the hypoglycemic activities of Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Labetalol.
Tolfenamic Acid
The risk or severity of hypotension can be increased when Labetalol is combined with Tolfenamic Acid.
Tolmetin
Tolmetin may decrease the antihypertensive activities of Labetalol.
Toloxatone
Toloxatone may increase the hypotensive activities of Labetalol.
Torsemide
Torasemide may increase the hypotensive activities of Labetalol.
Tramazoline
The risk or severity of adverse effects can be increased when Labetalol is combined with Tramazoline.
Trandolapril
Trandolapril may increase the hypotensive activities of Labetalol.
Tranilast
The risk or severity of hypotension can be increased when Labetalol is combined with Tranilast.
Tranylcypromine
The metabolism of Labetalol can be decreased when combined with Tranylcypromine.
Travoprost
Travoprost may increase the hypotensive activities of Labetalol.
Treprostinil
Treprostinil may increase the hypotensive activities of Labetalol.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Labetalol.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.
Trichlormethiazide
Labetalol may increase the hypotensive activities of Trichlormethiazide.
Trifluoperazine
Trifluoperazine may increase the hypotensive activities of Labetalol.
Triflupromazine
Triflupromazine may increase the hypotensive activities of Labetalol.
Trimebutine
The risk or severity of hypotension can be increased when Labetalol is combined with Trimebutine.
Trimeprazine
Alimemazine may increase the hypotensive activities of Labetalol.
Trimethadione
The risk or severity of hypotension can be increased when Labetalol is combined with Trimethadione.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Labetalol.
Tubocurarine
Tubocurarine may increase the bradycardic activities of Labetalol.
Tulobuterol
Labetalol may decrease the vasoconstricting activities of Tulobuterol.
Tyramine
The risk or severity of adverse effects can be increased when Labetalol is combined with Tyramine.
UNOPROSTONE
Labetalol may increase the hypotensive activities of Unoprostone.
Urapidil
Labetalol may increase the antihypertensive activities of Urapidil.
Valdecoxib
Valdecoxib may decrease the antihypertensive activities of Labetalol.
Valsartan
Valsartan may increase the hypotensive activities of Labetalol.
Vardenafil
Vardenafil may increase the hypotensive activities of Labetalol.
Varenicline
The risk or severity of adverse effects can be increased when Labetalol is combined with Varenicline.
Venlafaxine
The metabolism of Labetalol can be decreased when combined with Venlafaxine.
Verapamil
Verapamil may increase the hypotensive activities of Labetalol.
Vincamine
Labetalol may increase the hypotensive activities of Vincamine.
Vinpocetine
Labetalol may increase the hypotensive activities of Vinpocetine.
Xamoterol
Labetalol may decrease the vasoconstricting activities of Xamoterol.
Xylometazoline
Xylometazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Labetalol.
Ziconotide
The risk or severity of hypotension can be increased when Labetalol is combined with Ziconotide.
Zileuton
Zileuton may decrease the antihypertensive activities of Labetalol.
Ziprasidone
The metabolism of Labetalol can be decreased when combined with Ziprasidone.
Zofenopril
Labetalol may increase the hypotensive activities of Zofenopril.
Zomepirac
Zomepirac may decrease the antihypertensive activities of Labetalol.
Zonisamide
The risk or severity of hypotension can be increased when Labetalol is combined with Zonisamide.
